Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California.
Industry, Sector and Symbol
Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:AST
CUSIPN/A
Phone+1-510-4563805
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-403.38%
Return on Equity-79.80%
Return on Assets-59.45%
Miscellaneous
EmployeesN/A
Outstanding Shares55,510,000
Market Cap$102.89 million
Asterias Biotherapeutics (NYSEAMERICAN:AST) Frequently Asked Questions
What is Asterias Biotherapeutics' stock symbol?
Asterias Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AST."
How were Asterias Biotherapeutics' earnings last quarter?
Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) issued its earnings results on Thursday, August, 9th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of ($0.10). The biotechnology company had revenue of $0.11 million for the quarter, compared to analysts' expectations of $0.11 million. Asterias Biotherapeutics had a negative net margin of 403.38% and a negative return on equity of 79.80%. View Asterias Biotherapeutics' Earnings History.
When is Asterias Biotherapeutics' next earnings date?
What price target have analysts set for AST?
3 brokers have issued 1 year target prices for Asterias Biotherapeutics' stock. Their predictions range from $6.00 to $11.00. On average, they expect Asterias Biotherapeutics' stock price to reach $8.50 in the next year. This suggests a possible upside of 507.1% from the stock's current price. View Analyst Price Targets for Asterias Biotherapeutics.
What is the consensus analysts' recommendation for Asterias Biotherapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Asterias Biotherapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Asterias Biotherapeutics.
What are Wall Street analysts saying about Asterias Biotherapeutics stock?
Here are some recent quotes from research analysts about Asterias Biotherapeutics stock:
- 1. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We use a sum-of- the-parts approach, which ascribes a $440M risk-adjusted net present value (rNPV) to the AST-OPC1 program in AST-VAC programs in NSCLC and prostate cancer." (9/5/2018)
- 2. According to Zacks Investment Research, "Asterias Biotherapeutics, Inc. is a biotechnology company. It is focused on the field of regenerative medicine. The Company's technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. It develops therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields, with an initial focus on the therapeutic areas of neurology and oncology. Asterias Biotherapeutics, Inc. is based in Menlo Park, California. " (8/14/2018)
Are investors shorting Asterias Biotherapeutics?
Asterias Biotherapeutics saw a increase in short interest during the month of August. As of August 31st, there was short interest totalling 3,591,039 shares, an increase of 6.7% from the August 15th total of 3,365,104 shares. Based on an average daily volume of 117,847 shares, the days-to-cover ratio is presently 30.5 days. Currently, 10.9% of the shares of the stock are short sold. View Asterias Biotherapeutics' Current Options Chain.
Who are some of Asterias Biotherapeutics' key competitors?
Some companies that are related to Asterias Biotherapeutics include MediGene (MDG1), Oxford BioMedica (OXB), BioTime (BTX), Resverlogix (RVX), 22nd Century Group (XXII), Protalix Biotherapeutics (PLX), Neptune Technologies & Bioressources (NEPT), Monash IVF Group (MVF), ABcann Global (ABCN), Horizon Discovery Group (HZD), IMV (IMV), Faron Pharmaceuticals Oy (FARN), Bionomics (BNO), Fennec Pharmaceuticals (FRX) and ImmunoVaccine (IMMVF).
Who are Asterias Biotherapeutics' key executives?
Asterias Biotherapeutics' management team includes the folowing people:
- Mr. Michael H. Mulroy, Chief Exec. Officer, Pres & Director (Age 52)
- Dr. Edward D. Wirth III, M.D., Ph.D., Chief Medical Officer (Age 53)
- Dr. Katharine E. Spink, Consultant (Age 44)
- Mr. Stephen L. Cartt, Advisor & Director (Age 55)
- Mr. Ryan D. Chavez, CFO & Gen. Counsel (Age 42)
Has Asterias Biotherapeutics been receiving favorable news coverage?
News headlines about AST stock have trended somewhat positive on Friday, according to Accern. The research firm identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Asterias Biotherapeutics earned a media and rumor sentiment score of 0.18 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 46.57 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View Recent Headlines for Asterias Biotherapeutics.
Who are Asterias Biotherapeutics' major shareholders?
Asterias Biotherapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Millennium Management LLC (0.88%), BlackRock Inc. (0.38%), Creative Planning (0.33%), Paloma Partners Management Co (0.26%), Renaissance Technologies LLC (0.19%) and LMR Partners LLP (0.15%). Company insiders that own Asterias Biotherapeutics stock include Edward Wirth, Katharine E Spink and Michael H Mulroy. View Institutional Ownership Trends for Asterias Biotherapeutics.
Which major investors are selling Asterias Biotherapeutics stock?
Which major investors are buying Asterias Biotherapeutics stock?
How do I buy shares of Asterias Biotherapeutics?
Shares of AST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Asterias Biotherapeutics' stock price today?
One share of AST stock can currently be purchased for approximately $1.40.
How big of a company is Asterias Biotherapeutics?
Asterias Biotherapeutics has a market capitalization of $102.89 million.
How can I contact Asterias Biotherapeutics?
Asterias Biotherapeutics' mailing address is 6300 Dumbarton Cir, FREMONT, CA 94555-3644, United States. The biotechnology company can be reached via phone at +1-510-4563805.
MarketBeat Community Rating for Asterias Biotherapeutics (NYSEAMERICAN AST)
MarketBeat's community ratings are surveys of what our community members think about Asterias Biotherapeutics and other stocks. Vote "Outperform" if you believe AST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AST will underperform the S&P 500 over the long term. You may vote once every thirty days.
